Study details

Reference	Sullivan et al 2021: "Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging"

Study design

- X Individually-randomized parallel-group trial
- ☐ Cluster-randomized parallel-group trial
- ☐ Individually randomized cross-over (or other matched) trial

For the purposes of this assessment, the interventions being compared are defined as

Experimental:	EarlyCDT Lung test	Comparator:	Standard clinical care

Specify which outcome is being assessed for risk of bias	Rate of stage III/IV lung cancer within 2 years of randomisation
Specify the numerical result being assessed. In case of multiple alternative analyses being presented, specify the numeric result (e.g. RR = 1.52 (95% CI 0.83 to 2.77) and/or a reference (e.g. to a table, figure or paragraph) that uniquely defines the result being assessed.	HR 0.64 (95% CI 0.41–0.99)

Is the review team's aim for this result…?

- x to assess the effect of *assignment to intervention* (the 'intention-to-treat' effect)
- ☐ to assess the effect of *adhering to intervention* (the 'per-protocol' effect)

If the aim is to assess the effect of *adhering to intervention*, select the deviations from intended intervention that should be addressed (at least one must be checked):

- ☐ occurrence of non-protocol interventions
- ☐ failures in implementing the intervention that could have affected the outcome
- ☐ non-adherence to their assigned intervention by trial participants

Which of the following sources were <u>obtained</u> to help inform the risk-of-bias assessment? (tick as many as apply)

- x Journal article(s) with results of the trial
- x Trial protocol
- ☐ Statistical analysis plan (SAP)

- x Non-commercial trial registry record (e.g. ClinicalTrials.gov record)
- ☐ Company-owned trial registry record (e.g. GSK Clinical Study Register record)
- ☐ "Grey literature" (e.g. unpublished thesis)
- x Conference abstract(s) about the trial
- ☐ Regulatory document (e.g. Clinical Study Report, Drug Approval Package)
- ☐ Research ethics application
- ☐ Grant database summary (e.g. NIH RePORTER or Research Councils UK Gateway to Research)
- ☐ Personal communication with trialist
- ☐ Personal communication with the sponsor